The Zotect study: Effect of zoledronic acid (Zometa®) on Bone Metabolism in Patients with Nreast or Prostate cancer with Bone metastases.

被引：0
|
作者：
Gschwendt, J. [1 ]
Ziller, M. [2 ]
Kalder, M. [2 ]
Lux, C. [1 ]
Maurer, T. [1 ]
Muth, M. [3 ]
Schmidt, K. [3 ]
Hadji, P. [2 ]
机构：
[1] Klinikum RD Isar, Urol Klin, Munich, Germany
[2] Univ Marburg, Marburg, Germany
[3] Novartis Pharma GmbH, BU Onkol, Nurnberg, Germany
来源：
ONKOLOGIE | 2010年 / 33卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：204 / 204
页数：1
相关论文
共 50 条
  • [1] The ZOTECT study: Effect of zoledronic acid on bone metabolism in patients with bone metastases from prostate or breast cancer
    Hadji, Peyman
    Ziller, May
    Maurer, Tobias
    Autenrieth, Michael
    Muth, Mathias
    Ruebel, Amelie
    May, Christoph
    Birkholz, Katrin
    Diebel, Erhardt
    Gleissner, Jochen
    Rothe, Peter
    Gschwend, Juergen E.
    JOURNAL OF BONE ONCOLOGY, 2012, 1 (03) : 88 - 94
  • [2] Population pharmacokinetic model for zoledronic acid (zometa) in patients with bone metastases.
    Booth, BP
    Rahman, A
    Ibrahim, A
    Scher, N
    Williams, G
    Schran, H
    Ma, P
    Hsu, C
    Gobburu, JV
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 73 (02) : P67 - P67
  • [3] THE ZOTECT STUDY: EFFECT OF INTRAVENOUS ZOLEDRONIC ACID ON BONE METABOLISM IN PATIENTS WITH METASTATIC BONE DISEASE IN BREAST CANCER AND PROSTATE CANCER
    Gschwend, J.
    Ziller, M.
    Kalder, M.
    Muth, M.
    Ruebel, A.
    Schmidt, K.
    Hadji, P.
    ANNALS OF ONCOLOGY, 2010, 21 : 117 - 118
  • [4] The ZOTECT study: Effect of intravenous zoledronic acid on bone metabolism in patients with metastatic bone disease in prostate cancer (PC) and breast cancer (BC).
    Hadji, P.
    Ziller, M.
    Maurer, T.
    Muth, M.
    Ruebel, A.
    May, C.
    Birkholz, K.
    Gschwend, J. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [5] Zoledronic acid (ZOMETA): a significant improvement in the treatment of bone metastases
    Nagy, Z
    PATHOLOGY & ONCOLOGY RESEARCH, 2005, 11 (03) : 186 - 187
  • [6] Financial impact of coverage for zoledronic acid and denosumab in cancer patients with bone metastases.
    Russell, M. W.
    Bell, M. J.
    Namjoshi, M.
    Miller, J. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [7] Economic evaluation of denosumab compared with zoledronic acid in patients with hormone-refractory prostate cancer with bone metastases.
    Yu, A. P.
    Namjoshi, M.
    Xie, J.
    Parikh, K.
    Wu, E. Q.
    Guo, A.
    Culver, K. W.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [8] Effect of Degarelix Administration on Bone Health in Prostate Cancer Patients Without Bone Metastases. The Blade Study
    Palumbo, Carlotta
    Dalla Volta, Alberto
    Zamboni, Stefania
    Mazziotti, Gherardo
    Zamparini, Manuel
    Triggiani, Luca
    Borghetti, Paolo
    Maffezzoni, Filippo
    Bresciani, Roberto
    Rinaudo, Luca
    Valcamonico, Francesca
    Farina, Davide
    Magrini, Stefano Maria
    Antonelli, Alessandro
    Simeone, Claudio
    Berruti, Alfredo
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2022, 107 (12): : 3398 - 3407
  • [9] The use of zoledronic acid in patients with bone metastases from prostate carcinoma: Effect on analgesic response and bone metabolism biomarkers
    Fulfaro, F
    Leto, G
    Badalamenti, G
    Arcara, C
    Cicero, G
    Valerio, MR
    Di Fede, G
    Russo, A
    Vitale, A
    Rini, GB
    Casuccio, A
    Intrivici, C
    Gebbia, N
    JOURNAL OF CHEMOTHERAPY, 2005, 17 (05) : 555 - 559
  • [10] IMPACT OF ZOLEDRONIC ACID ON FRACTURES AND MORTALITY IN PATIENTS WITH PROSTATE CANCER AND BONE METASTASES
    Henk, H. J.
    Kaura, S.
    EUROPEAN UROLOGY SUPPLEMENTS, 2010, 9 (02) : 284 - 285
12345